Postoperative Adjuvant Chemotherapy or Chemoradiation Versus Surgery Alone for Thoracic Pathological Node Positive Esophageal Cancer: A Propensity Score-Matched Analysis (APEC Study 2)
Q. Wang,T. Li,Y. Han,Q. Li,L. Peng,T. Xie,Q. Fang,X. Yang,X. Zhuang,W. Dai,Y. Jiang,Y. Wang,J. Lv,L. Wu,B. Cao,J. Lang
DOI: https://doi.org/10.1016/j.ijrobp.2019.06.111
2019-01-01
Abstract:No completed randomized controlled trial has compared long-term survival outcomes of patients receiving postoperative adjuvant chemotherapy (POCT group) and chemoradiation therapy (POCRT group) compare with surgery alone (S group) directly for Pathological node positive Thoracic Esophageal Squamous cell cancer (N+ TESCC). Patients with N+ TESCC receiving either adjuvant chemotherapy or chemoradiation after esophagectomy were identified at Sichuan Cancer Hospital from January 2009 to December 2017. Univariate analysis compared patient, tumor, and postoperative outcome characteristics. Kaplan-Meier analysis was performed to compare overall survival (OS) and disease free survival (DFS) by adjuvant therapy type. Propensity score matching was used to create patient groups that were balanced across several covariates (n= 281 in each group). Finally, a Cox proportional hazards model was fitted to identify variables associated with increased mortality hazard. From 2009 to 2017, a total of 1490 of N+ TESCC patients received operation whereas 283(19.0%) received POCRT, 563 (37.8%) received POCT, 644(43.2%) received Surgery alone. Patients who received POCRT and POCT were more likely to achieve a longer 5-year OS (38.8% and 30.0% versus 27.3%, p = 0.005) and DFS (36.4% and 27.5% versus 25.2%, p = 0.089). These data were confirmed in the matched samples (5-year OS, 38.1% and 30.9 % versus 20.5% [p = 0.006]; DFS, 35.9% and 28.2% versus 19.6% [p = 0.017]). Multivariate Cox analyses in the matched samples revealed that postoperative POCRT and POCT were independently associated with longer OS (hazard ratio = 0.878, 95% confidence interval: 0.818 - 0.942, p < 0.001) and longer DFS (hazard ratio = 0.931, 95% confidence interval: 0.869–0.997, p = 0.042 ) than resection alone. Subgroup analysis found: for N1-2 patients, POCRT and POCT have longer 5-year OS (p=0.001) and DFS (p=0.034) than S group. For N3 patients, postoperative adjuvant therapy cannot prolong the OS and DFS than resection alone. Postoperative adjuvant chemoradiation therapy and chemotherapy are strongly associated with improved OS and DFS in patients with N positive TESCC. A multicenter, randomized phase III clinical trial is warranted to confirm these findings.